MedTrace Logo

Preserving Geriatric Muscle With an Osteoporosis Medication

NCT06118905 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2026-02-10

No results posted yet for this study

Summary

Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.

Conditions

Interventions

DRUG

Denosumab 60 MG/ML

Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV

DRUG

Zoledronic Acid 5Mg/Bag 100Ml Infusion

Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo

Sponsors & Collaborators

  • Susan L. Greenspan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2029-02-28
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118905 on ClinicalTrials.gov